

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Dinutuximab for treating high-risk neuroblastoma [ID799]

Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • United Therapeutics (dinutuximab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Children's Cancer and Leukaemia Group • Neuroblastoma UK • Solving Kids Cancer (<i>formerly Neuroblastoma Children's Cancer Alliance (NCCA UK)</i>) <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Cancer Research UK • Royal College of Nursing • Royal College of Paediatrics and Child Health • Royal College of Physicians <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • Welsh Government 	<p><u>General</u></p> <ul style="list-style-type: none"> • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Alliance Pharma (isotretinoin) (CA&U not returned, not participating) • Roche (isotretinoin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • National Cancer Research Institute <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • None

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.